ClinicalTrials.gg
RecruitingNCT06993844Updated Oct 13, 2026

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of ETX-636 dose escalation and ETX-636 dose escalation in combination with fulvestrant in Advanced Solid Tumors and Advanced Breast Cancer, sponsored by Ensem Therapeutics. Recruiting at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionBreast NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Breast Neoplasms
Why
  1. The study's listed conditions name Breast Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ensem Therapeutics · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Oct 13, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
233
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

Read the detailed description

Brief Summary: This is a Phase 1/2, open-label, multicenter, 3-part study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of ETX-636 in participants with advanced solid tumors harboring a PIK3CA mutation.

Part A will evaluate escalating doses of ETX-636 as monotherapy in participants with advanced solid tumors. Part B will evaluate escalating doses of ETX-636 as combination therapy with fixed dose fulvestrant in participants with hormone receptor positive (HR+), HER2 negative (HER2-) locally advanced or metastatic breast cancer. Part C will be a combination therapy expansion in participants with HR+, HER2- locally advanced or metastatic breast cancer.

Each study part will include a 28-day screening period, followed by treatment with ETX-636 monotherapy or combination therapy.

02

Conditions studied

  • Advanced Solid Tumors
  • Advanced Breast Cancer

Keywords

  • cancer
  • breast cancer
  • solid tumors
  • PIK3CA
  • PI3Kα inhibitor
  • Breast Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Breast Diseases
  • HER2-negative breast cancer
  • HR-positive breast cancer
  • Gynecologic cancer
  • Endometrial cancer
  • Ovarian cancer
  • Cervical cancer
  • Head and neck cancer
  • Head and neck squamous cell carcinoma
  • Fulvestrant
  • Antineoplastic Agents
  • PI3Kα
  • PI3K alpha
  • PI3Kα mutation
  • Alpelisib
  • Estrogen Receptor Antagonists
  • Estrogen Antagonists
  • Hormone Receptor Antagonists
  • Hormone Antagonists
  • Hormones, Hormone Substitutes, and Hormone Antagonists
  • Physiological Effects of Drugs
  • PIK3CA mutation
03

In context

Breast Neoplasms Reclassified

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's planned enrollment of 233 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Ensem Therapeutics is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or locally advanced and unresectable solid tumor that has progressed on or after at least one available therapy.
  • Tumor harboring an activating PIK3CA mutation detected in either tumor tissue or ctDNA.
  • At least 1 or evaluable disease per v1.1.
  • An performance status score of 0 or 1.
  • Adequate organ function.

Additional key inclusion criterion for Parts B and C:

- Confirmed metastatic or locally advanced HR+/- breast cancer not amenable to surgical resection with curative intent and must have received at least 1 prior CDK4/6 inhibitor and at least 1 prior anti-estrogen therapy.

Key Exclusion Criteria:

  • Has history (within ≤2 years before screening) of a solid tumor or hematological that is histologically distinct from the cancers being studied.
  • Has symptomatic brain or spinal metastases or a known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement.
  • Has an established diagnosis of diabetes mellitus type 1 or has uncontrolled diabetes mellitus type 2.
  • Has received treatment with any local or systemic anticancer therapy or anticancer agent within 14 days prior to start of treatment.
  • Has toxicities from previous anticancer therapies that have not resolved to baseline levels with the exception of alopecia and peripheral neuropathy.
  • Has had radiotherapy outside the target tumor lesions within 14 days prior to start of treatment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
233 participants (estimated)

Study arms

  • Experimental
    Part A Dose Escalation Monotherapy (Advanced Solid Tumors with PIK3CA mutation)

    Part A is a dose escalation monotherapy of ETX-636 in advanced solid tumors with PIK3CA mutation

    Drug: ETX-636 dose escalation

  • Experimental
    Part B Dose Escalation Combination Therapy (HR+/HER2- locally advanced or metastatic breast cancer)

    Part B is a dose escalation combination therapy in HR+/HER2- locally advanced or metastatic breast cancer. The study treatment will be ETX-636, a pan-mutant-selective PI3Kα inhibitor, in combination with fulvestrant (Faslodex) at a fixed dose of 500 mg IM.

    Drug: ETX-636 dose escalation in combination with fulvestrant

  • Experimental
    Part C Dose Expansion Combination Therapy (HR+/HER2- locally advanced or metastatic breast cancer)

    Part B is a dose expansion combination therapy in HR+/HER2- locally advanced or metastatic breast cancer. The study treatment will be ETX-636, a pan-mutant-selective PI3Kα inhibitor, in combination with fulvestrant (Faslodex) at a fixed dose of 500 mg IM.

    Drug: ETX-636 dose expansion in combination with fulvestrant

Interventions

  • DrugETX-636 dose escalation

    ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet that will be taken once per day in 28-day cycles, to evaluate escalating dose levels.

  • DrugETX-636 dose escalation in combination with fulvestrant

    Drug page: Fulvestrant

    ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet. ETX-636 will be taken in combination with fulvestrant in 28-day cycles, to evaluate escalating dose levels. EXT-636 is an oral tablet that will be taken once per day. Fulvestrant will be administered as an injection 2 weeks apart in the first 28 days, followed by monthly injections.

    Also known as: Faslodex

  • DrugETX-636 dose expansion in combination with fulvestrant

    Drug page: Fulvestrant

    ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet. ETX-636 will be taken in combination with fulvestrant in 28-day cycles, to expand selected dose levels. EXT-636 is an oral tablet that will be taken once per day. Fulvestrant will be administered as an injection 2 weeks apart in the first 28 days, followed by monthly injections.

    Also known as: Faslodex

06

What researchers measure

Primary outcomes

  1. Evaluate Safety and Tolerability of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part B

    Proportion of participants who experience at least 1 Dose Limiting Toxicity (DLT)

    Time frame: First 28 days of treatment

  2. Evaluate Safety and Tolerability of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part B

    Incidence of AEs, treatment discontinuations due to AEs, changes from baseline in laboratory assessments, ECGs and vital signs.

    Time frame: Average of 6 months

  3. Select the Recommended Phase 2 Dose(s) (RP2D) in Part B to be further explored in Part C (combination therapy expansion)

    Safety Parameters as described for primary outcomes

    Time frame: Average of 6 months

  4. Evaluate efficacy of ETX-636 plus fulvestrant combination therapy at the RP2D(s) in Part C

    ORR and CBR according to RECIST v1.1

    Time frame: Average of 6 months

Secondary outcomes

  1. Characterize the Cmax (PK) of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part B

    Maximum observed plasma concentration (Cmax) of ETX-636

    Time frame: First 2 treatment cycles (each cycle is 28 days)

  2. Characterize the Tmax (PK) of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part B

    Calculated time to reach maximum observed plasma concentration of ETX-636

    Time frame: First 2 treatment cycles (each cycle is 28 days)

  3. Characterize the AUC (PK) of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part B

    Calculated area under the plasma concentration curve (AUC) of ETX-636

    Time frame: First 2 treatment cycles (each cycle is 28 days)

  4. Measure PD effects of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part B and ETX-636 plus fulvestrant at the RP2D(s) in Part C

    Change from baseline in ctDNA levels; Change from baseline in PD markers in paired biopsies

    Time frame: First 3 cycles (each cycle is 28 days)

  5. Changes in fasting blood glucose (All Parts)

    Measured by fasting blood glucose

    Time frame: Average of 6 months

  6. Changes in longitudinal glucose metabolism (All Parts)

    Measured by HbA1c

    Time frame: Average of 6 months

  7. Assess preliminary efficacy of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part B

    Objective response rate (ORR) and clinical benefit rate (CBR) based on RECIST v1.1

    Time frame: Average of 6 months

  8. Evaluate measures of efficacy of ETX-636 plus fulvestrant combination therapy at the RP2D(s) in Part C

    Time to response (TTR) according to RECIST v1.1

    Time frame: Average of 6 months

  9. Evaluate additional measures of efficacy of ETX-636 plus fulvestrant combination therapy at the RP2D(s) in Part C

    Duration of response (DoR) according to RECIST v1.1

    Time frame: Average of 6 months

  10. Evaluate additional measures of efficacy of ETX-636 plus fulvestrant combination therapy at the RP2D(s) in Part C

    Disease control rate (DCR) according to RECIST v1.1

    Time frame: Average of 6 months

  11. Evaluate additional measures of efficacy of ETX-636 plus fulvestrant combination therapy at the RP2D(s) in Part C

    Progression free survival (PFS) according to RECIST v1.1

    Time frame: Average of 6 months

  12. Evaluate Safety of ETX-636 plus fulvestrant combination therapy at the RP2Ds in Part C

    Incidence of adverse events graded according to CTCAE v5.0

    Time frame: Average of 6 months

  13. Evaluate tolerability of ETX-636 plus fulvestrant combination therapy at the RP2Ds in Part C

    Incidence of adverse events graded according to CTCAE v5.0

    Time frame: Average of 6 months

  14. Characterize the PK of ETX-636 plus fulvestrant using population PK modeling (Part C, to be reported separately)

    Plasma concentrations

    Time frame: First 2 treatment cycles (each cycle is 28 days)

07

Study locations

15 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 24 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2025
First posted
May 29, 2025
StartActual
Jun 10, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: j•••@ensemtx.com · •••4993→l•••@ensemtx.com · •••4993; removed m•••@ensemtx.com · •••4993. See the current contact
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Contact Study contact changed: j•••@ensemtx.com · •••4993→l•••@ensemtx.com · •••4993; removed m•••@ensemtx.com · •••4993. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06993844
Lead sponsor
Ensem Therapeutics
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Jun 10, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Lori Cykowski
Contact
lori.cykowski@Ensemtx.com
1-617-383-4993

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion